Regulation of Signal Transducer and Activator of Transcription 1 (STAT1) and STAT1-Dependent Genes by RET/PTC (Rearranged in Transformation/Papillary Thyroid Carcinoma) Oncogenic Tyrosine Kinases
- 1 November 2004
- journal article
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 18 (11) , 2672-2684
- https://doi.org/10.1210/me.2004-0168
Abstract
Chimeric RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncoproteins are constitutively active tyrosine kinases found in thyroid papillary carcinoma and nonneoplastic Hashimoto’s thyroiditis. Although several proteins have been identified to be substrates of RET/PTC kinases, the pathogenic roles played by RET/PTC in malignant and benign thyroid diseases and the molecular mechanisms that are involved are not fully understood. We found that RET/PTC expression phosphorylates the Y701 residue of STAT1, a type II interferon (IFN)-responsive protein. RET/PTC-mediated signal transducer and activator of transcription 1 (STAT1) phosphorylation requires RET/PTC kinase activity to be intact but other tyrosine kinases, such as Janus kinases or c-Src, are not involved. RET/PTC-induced STAT1 transcriptional activation was not inhibited by suppressor of cytokine signaling-1 or -3, or protein inhibitors of activated STAT3 [(protein inhibitor of activated STAT (PIAS3)], but PIAS1 strongly repressed the RET/PTC-induced transcriptional activity of STAT1. RET/PTC-induced STAT1 activation caused IFN regulatory factor-1 expression. We found that STAT1 and IFN regulatory factor-1 cooperated to significantly increase transcription from type IV IFN-γresponsive promoters of class II transactivator genes. Significantly, cells stably expressing RET/PTC expressed class II transactivator and showed enhanced de novo membrane expression of major histocompatibility complex (MHC) class II proteins. Furthermore, RET/PTC1-bearing papillary thyroid carcinoma cells strongly expressed MHC class II (human leukocyte-associated antigen-DRα) genes, whereas the surrounding normal tissues did not. Thus, RET/PTC is able to phosphorylate and activate STAT1. This may lead to enhanced MHC class II expression, which may explain why the tissues surrounding RET/PTC-positive cancers are infiltrated with lymphocytes. Such immune response-promoting activity of RET/PTC may also relate to the development of Hashimoto’s thyroiditis.Keywords
This publication has 44 references indexed in Scilit:
- CR6-interacting Factor 1 Interacts with Gadd45 Family Proteins and Modulates the Cell CycleJournal of Biological Chemistry, 2003
- Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenesOncogene, 2003
- Molecular Rearrangements and Morphology in Thyroid CancerThe American Journal of Pathology, 2002
- Docking Protein FRS2 Links the Protein Tyrosine Kinase RET and Its Oncogenic Forms with the Mitogen-Activated Protein Kinase Signaling CascadeMolecular and Cellular Biology, 2001
- Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoproteinOncogene, 2001
- ret/PTC-1 Activation in Hashimoto ThyroiditisInternational Journal of Surgical Pathology, 2000
- Identification of SOCS-3 as a Potential Mediator of Central Leptin ResistanceMolecular Cell, 1998
- c-Src Activates both STAT1 and STAT3 in PDGF-Stimulated NIH3T3 CellsBiochemical and Biophysical Research Communications, 1997
- Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src OncoproteinScience, 1995
- Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cellsNature, 1984